413 related articles for article (PubMed ID: 28498807)
1. Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells.
Lu WQ; Hu YY; Lin XP; Fan W
Oncotarget; 2017 Jul; 8(27):44171-44185. PubMed ID: 28498807
[TBL] [Abstract][Full Text] [Related]
2. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
[TBL] [Abstract][Full Text] [Related]
3. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer.
Wang X; Zhang H; Yang H; Bai M; Ning T; Deng T; Liu R; Fan Q; Zhu K; Li J; Zhan Y; Ying G; Ba Y
Mol Oncol; 2020 Mar; 14(3):539-555. PubMed ID: 31901148
[TBL] [Abstract][Full Text] [Related]
4. miR-506 enhances the sensitivity of human colorectal cancer cells to oxaliplatin by suppressing MDR1/P-gp expression.
Zhou H; Lin C; Zhang Y; Zhang X; Zhang C; Zhang P; Xie X; Ren Z
Cell Prolif; 2017 Jun; 50(3):. PubMed ID: 28217977
[TBL] [Abstract][Full Text] [Related]
5. Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
Li Q; Zhang D; Chen X; He L; Li T; Xu X; Li M
Sci Rep; 2015 Nov; 5():16082. PubMed ID: 26542452
[TBL] [Abstract][Full Text] [Related]
6. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
[TBL] [Abstract][Full Text] [Related]
7. Effects of shRNA-Mediated Silencing of PKM2 Gene on Aerobic Glycolysis, Cell Migration, Cell Invasion, and Apoptosis in Colorectal Cancer Cells.
Yan XL; Zhang XB; Ao R; Guan L
J Cell Biochem; 2017 Dec; 118(12):4792-4803. PubMed ID: 28543190
[TBL] [Abstract][Full Text] [Related]
8. Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment.
Zhou Y; Huang Z; Su J; Li J; Zhao S; Wu L; Zhang J; He Y; Zhang G; Tao J; Zhou J; Chen X; Peng C
Int J Cancer; 2020 Jul; 147(1):139-151. PubMed ID: 31652354
[TBL] [Abstract][Full Text] [Related]
9. CircAGFG1 absence decreases PKM2 expression to enhance oxaliplatin sensitivity in colorectal cancer in a miR-7-5p-dependent manner.
Chen J; Wang H; Tang M
J Chemother; 2024 May; 36(3):208-221. PubMed ID: 37691430
[TBL] [Abstract][Full Text] [Related]
10. Lupeol alters ER stress-signaling pathway by downregulating ABCG2 expression to induce Oxaliplatin-resistant LoVo colorectal cancer cell apoptosis.
Chen MC; Hsu HH; Chu YY; Cheng SF; Shen CY; Lin YJ; Chen RJ; Viswanadha VP; Lin YM; Huang CY
Environ Toxicol; 2018 May; 33(5):587-593. PubMed ID: 29436100
[TBL] [Abstract][Full Text] [Related]
11. Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer.
Dong Y; Wang Z; Xie GF; Li C; Zuo WW; Meng G; Xu CP; Li JJ
Mol Cancer; 2017 Mar; 16(1):71. PubMed ID: 28356150
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
[TBL] [Abstract][Full Text] [Related]
13. Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo.
Wang Y; Zhao H; Zhao P; Wang X
Cancer Biomark; 2021; 32(2):221-230. PubMed ID: 34092620
[TBL] [Abstract][Full Text] [Related]
14. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP.
Tang H; Liu YJ; Liu M; Li X
Anticancer Drugs; 2007 Jul; 18(6):633-9. PubMed ID: 17762391
[TBL] [Abstract][Full Text] [Related]
15. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
16. Apoptin Inhibits Glycolysis and Regulates Autophagy by Targeting Pyruvate Kinase M2 (PKM2) in Lung Cancer A549 Cells.
Song G; Shang C; Zhu Y; Xiu Z; Li Y; Yang X; Ge C; Han J; Jin N; Li Y; Li X; Fang J
Curr Cancer Drug Targets; 2024; 24(4):411-424. PubMed ID: 36284386
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer.
Taniguchi K; Sugito N; Kumazaki M; Shinohara H; Yamada N; Nakagawa Y; Ito Y; Otsuki Y; Uno B; Uchiyama K; Akao Y
Cancer Lett; 2015 Jul; 363(1):17-27. PubMed ID: 25818238
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression.
Xu X; Li J; Sun X; Guo Y; Chu D; Wei L; Li X; Yang G; Liu X; Yao L; Zhang J; Shen L
Oncotarget; 2015 Sep; 6(28):26161-76. PubMed ID: 26317652
[TBL] [Abstract][Full Text] [Related]
19. MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in cervical cancer.
Guo M; Zhao X; Yuan X; Jiang J; Li P
Oncotarget; 2017 Apr; 8(17):28226-28236. PubMed ID: 28415668
[TBL] [Abstract][Full Text] [Related]
20. WBSCR22 confers oxaliplatin resistance in human colorectal cancer.
Yan D; Tu L; Yuan H; Fang J; Cheng L; Zheng X; Wang X
Sci Rep; 2017 Nov; 7(1):15443. PubMed ID: 29133897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
